Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. - - PowerPoint PPT Presentation

▶
recenti topic issues dalla letteratura non br br onj dr
SMART_READER_LITE
LIVE PREVIEW

Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. - - PowerPoint PPT Presentation

Feb 06, 2023 258 likes •814 views

Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. ARDUINO, DDS, MSC, PHD SCUOLA DI MEDICINA DIPARTIMENTO DI SCIENZE CHIRURGICHE UNIVERSITA DEGLI STUDI DI TORINO CIR DENTAL SCHOOL Jaw osteonecrosis. . When did it it

slide-1
SLIDE 1

Recenti TOPIC-ISSUES dalla letteratura non-BR

BR-ONJ

  • DR. PAOLO G. ARDUINO, DDS, MSC, PHD

SCUOLA DI MEDICINA – DIPARTIMENTO DI SCIENZE CHIRURGICHE UNIVERSITA’ DEGLI STUDI DI TORINO – CIR DENTAL SCHOOL

slide-2
SLIDE 2

Jaw osteonecrosis. . When did it it start?

slide-3
SLIDE 3

BRONJ 2003

slide-4
SLIDE 4

BRONJ 2003

slide-5
SLIDE 5

Bisphosphonates-related Osteonecrosis of the Jaw

slide-6
SLIDE 6
slide-7
SLIDE 7

MRONJ 2014

slide-8
SLIDE 8

Medication-related Osteonecrosis of the Jaw

slide-9
SLIDE 9

MRONJ _ definition

slide-10
SLIDE 10

MRONJ (medication?)

slide-11
SLIDE 11

MRONJ (medication?)

slide-12
SLIDE 12
slide-13
SLIDE 13

1.

  • 1. LITERATURE REVIEW (non-BR-ONJ)

20142018

slide-14
SLIDE 14

2014-2018 (march)

slide-15
SLIDE 15

2014-2018 (march)

slide-16
SLIDE 16

2014-2018 (march)

slide-17
SLIDE 17

2014-2018 (march)

slide-18
SLIDE 18

2014-2018 (march)

slide-19
SLIDE 19

2014-2018 (21st of April)

  • Denosumab
  • Bevacizumab
  • Sunitinib
  • Aflibercept
  • Axitinib
  • Everolimus
  • Methotrexate
  • Imatinib
  • Raloxifene
  • Infliximab
  • Erlotinib
  • Dasatinib
  • Rituximab
  • Imatinib
  • Adalimumab
  • Regorafenib
  • Sorafenib
  • Ipilimumab
  • Cabozantinib
  • Romosozumab
slide-20
SLIDE 20

2014-2018

  • De

Denosu sumab

  • Bevacizumab  a.a.g.
  • Sunitinib  i.RTK
  • Aflibercept  a.a.g.
  • Axitinib  i.RTK
  • Everolimus  i.mTOR
  • Methotrexate  i.s.
  • Imatinib  i.RTK
  • Raloxifene  SERMs
  • Infliximab  a.TNF
  • Erlotinib  i.RTK
  • Dasatinib  i.RTK
  • Rituximab  a.CD20
  • Imatinib  i.RTK
  • Adalimumab  a.TNF
  • Regorafenib  i.RTK
  • Sorafenib  a.FAK
  • Ipilimumab  anti-CTLA-4
  • Cabozantinib  i.RTK
  • Romosozumab  s.m.a.
  • Regorafenib  a.a.g.
slide-21
SLIDE 21

MRONJ _ incidence

slide-22
SLIDE 22
slide-23
SLIDE 23

MRONJ _ incidence

slide-24
SLIDE 24

non-BR BR-ONJ _ incidence worldwide

slide-25
SLIDE 25
slide-26
SLIDE 26
slide-27
SLIDE 27

non-BR BR-ONJ _ incidence

  • 1 case per 666 cancer patients treated
  • 1 case per 10.000 osteoporotic patients
slide-28
SLIDE 28
slide-29
SLIDE 29
slide-30
SLIDE 30
slide-31
SLIDE 31

non-BR BR-ONJ _ incidence Piedmont

slide-32
SLIDE 32
slide-33
SLIDE 33

non-BR BR-ONJ _ difference with BRONJ?

slide-34
SLIDE 34

non-BR BR-ONJ _ difference with BRONJ?

  • No difference in comorbidities
slide-35
SLIDE 35
slide-36
SLIDE 36

non-BR BR-ONJ _ difference with BRONJ?

  • No clinical differences
slide-37
SLIDE 37

non-BR BR-ONJ _ difference with BRONJ?

  • No radiological differences
slide-38
SLIDE 38

non-BR BR-ONJ _ difference with BRONJ?

slide-39
SLIDE 39
slide-40
SLIDE 40
slide-41
SLIDE 41
slide-42
SLIDE 42
slide-43
SLIDE 43
slide-44
SLIDE 44

non-BR BR-ONJ _ difference with BRONJ?

  • Prevention differences?
slide-45
SLIDE 45

non-BR BR-ONJ _ difference with BRONJ?

slide-46
SLIDE 46

non-BR BR-ONJ _ difference with BRONJ?

slide-47
SLIDE 47

non-BR BR-ONJ _ difference with BRONJ?

  • Outcome differences?
slide-48
SLIDE 48
slide-49
SLIDE 49
slide-50
SLIDE 50
slide-51
SLIDE 51
slide-52
SLIDE 52

non-BR BR-ONJ _ Take home message

slide-53
SLIDE 53

non-BR BR-ONJ _ Take home message

  • Denosumab, bevacizumab, sunitinib
  • < incidence
  • Probably differences in the duration of therapy (no dose cumulative)
  • Probably better surgical outcome (no data on medical one)
  • Difficulties in the correct classification () and nomenclature
  • New other drugs? ….incoming
slide-54
SLIDE 54